The US Food and Drug Administration (FDA) has added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) about increased risk for severe hypocalcemia in patients with advanced ...
The use of the osteoporosis drug denosumab (Prolia) to prevent fractures associated with advanced chronic kidney disease (CKD) in patients on kidney dialysis significantly increases the risk for ...
Worsening CKD was progressively associated with denosumab-induced hypocalcemia warranting emergency treatment. Denosumab use carries a higher risk for emergency hypocalcemia compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback